CLEVELAND, July 9, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Palos Health, in partnership with Loyola Medicine, has installed ViewRay's MRIdian® Linac System for MR image-guided radiation therapy at its Palos Health South Campus in Orland Park, Illinois. Palos Health becomes the first community hospital in the United States, and the only center in Illinois with the company's next generation linear accelerator-based system.
MR image-guided radiotherapy represents the latest advance in the field of radiation oncology. The anatomical detail only available with MR soft tissue imaging enables daily on-table treatment plan adaptation, allowing clinicians to quickly and dynamically adjust for anatomical changes that may naturally occur each day throughout the patient's course of treatment. The technology also allows oncologists to visualize and actively track the unique contours of the tumor and surrounding organs during radiation delivery using a non-ionizing, streaming video perspective unavailable until now. Combined, these capabilities provide the Palos Health clinical team with the tools to potentially improve tumor targeting precision and thus allow for delivery of higher, and potentially more effective, radiation doses.
"We are proud to be the first in our region to offer one of the most exciting advances in cancer care – MR image-guided radiotherapy. The ability to see, adapt and treat with unprecedented clarity and improved accuracy will be of great benefit to our patients in Chicagoland," said William Small Jr., M.D., FACRO, FACR, FASTRO, professor and chair of the Department of Radiation Oncology and director of the Cardinal Bernardin Cancer Center at Loyola University.
"MRIdian presents new opportunities for real-time imaging and motion management, allowing us to treat tumors that move with respiration or other anatomical changes more precisely, and even address many cancers that may previously have been difficult to treat with radiation," said Raymond B. Wynn, M.D., FACR, Professor, Vice Chairman of Clinical Operations Department of Radiation Oncology Loyola University & Medical Director Radiation Oncology at Loyola Center for Cancer Care and Research at Palos." We look forward to sharing MRIdian's benefits with our patients throughout Chicago."
The MRIdian Linac installation is the result of a partnership between Loyola Medicine and Palos Health intended to bring renowned oncology expertise, cutting-edge technology and coordinated, collaborative patient care to patients in the suburbs of Chicago.
"At Palos Health, we're committed to delivering the most advanced cancer therapies to the patients we serve, so we're really proud to be an early adopter of this important advance in cancer care," said Terrence Moisan, M.D., chief executive officer of Palos Health. "It's exciting to be the first community hospital to incorporate the MRIdian Linac system, as we believe MR image-guided radiation therapy will become a standard of care for all radiation oncology departments in the future."
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include the advancement of science, and the ability of MRI-guided radiation therapy programs to enable more treatment options, improved tumor targeting precision and higher, more effective, radiation dose. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
SOURCE ViewRay, Inc.